Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $227,043 | $251,455 | $477,706 | $313,837 |
| % Growth | -9.7% | -47.4% | 52.2% | – |
| Cost of Goods Sold | $38,549 | $54,005 | $204,216 | $129,690 |
| Gross Profit | $188,494 | $197,450 | $273,490 | $184,147 |
| % Margin | 83% | 78.5% | 57.3% | 58.7% |
| R&D Expenses | $424,061 | $580,621 | $1,052,643 | $1,149,662 |
| G&A Expenses | $246,161 | $385,025 | $1,429,799 | $862,952 |
| SG&A Expenses | $246,161 | $385,025 | $1,429,799 | $862,952 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $78,029 | $96,210 | $0 | $0 |
| Operating Expenses | $748,251 | $1,061,856 | $2,482,442 | $2,012,614 |
| Operating Income | -$559,757 | -$864,406 | -$2,208,952 | -$1,828,467 |
| % Margin | -246.5% | -343.8% | -462.4% | -582.6% |
| Other Income/Exp. Net | $12,249 | -$28,534 | $87,553 | -$9,655 |
| Pre-Tax Income | -$547,508 | -$892,940 | -$2,121,399 | -$1,838,122 |
| Tax Expense | -$479 | -$71 | -$15,027 | -$1,480 |
| Net Income | -$547,029 | -$892,869 | -$2,104,929 | -$1,830,047 |
| % Margin | -240.9% | -355.1% | -440.6% | -583.1% |
| EPS | -10.54 | -18.37 | -50.15 | -53.83 |
| % Growth | 42.6% | 63.4% | 6.8% | – |
| EPS Diluted | -10.54 | -18.4 | -50.2 | -55.53 |
| Weighted Avg Shares Out | 51,895 | 48,525 | 41,933 | 32,954 |
| Weighted Avg Shares Out Dil | 51,895 | 48,611 | 41,996 | 34,009 |
| Supplemental Information | – | – | – | – |
| Interest Income | $38,612 | $57,217 | $20,262 | $837 |
| Interest Expense | $94 | $93 | $106 | $2,373 |
| Depreciation & Amortization | $63,020 | $71,554 | $61,634 | $29,076 |
| EBITDA | -$484,394 | -$821,293 | -$2,059,659 | -$1,806,673 |
| % Margin | -213.3% | -326.6% | -431.2% | -575.7% |